Recent Advances in Pathogenesis, Diagnostic Imaging, and Treatment of Sjögren's Syndrome

Yoshiro Horai,Toshimasa Shimizu,Hideki Nakamura,Atsushi Kawakami

DOI: https://doi.org/10.3390/jcm13226688

IF: 3.9

2024-11-08

Journal of Clinical Medicine

Abstract:It is our pleasure to present the Special Issue "Diagnosis and Treatment of Sjögren's Syndrome" to the readers of the Journal of Clinical Medicine [...]

medicine, general & internal

What problem does this paper attempt to address?

Advances in the Pathogenesis and Treatment of Primary Sj(o)gren's Syndrome

YAO Hong-liang,ZHU Ke-jian

DOI: https://doi.org/10.3760/cma.j.issn.1673-4173.2013.05.004

2013-01-01

International Journal of Dermatology and Venereology

Abstract:Sj(o)gren's syndrome(SS)is a chronic autoimmune inflammatory disease characterized by predominant infiltration of lymphocytes in exocrine glands as well as presence of several autoantibodies in sera.Primary SS(pSS)is the condition in the absence of other definitively diagnosed autoimmune diseases.The pathogenesis of pSS remains unclear.Currently,pSS is considered to be induced by multiple environmental factors and endogenous antigens,which trigger a self-perpetuating inflammatory response in susceptible individuals,lead to abnormal cellular and humoral immunity followed by the impairment of exocrine glands,production of autoantibodies and damage to target organs.Although no ideal therapy is available,biological agents have offered new clues to the treatment of pSS.
Pathogenesis and diagnostic and therapeutic characteristics of Sjogren's syndrome based on TCM theory of five zang-organs

Qing WANG,Yilian CHEN,Guolin WU,Wenwen LU,Guoyou YU

DOI: https://doi.org/10.3969/j.issn.1006-2157.2017.11.016

2017-01-01

Abstract:Sjogren's syndrome (SS),named as dry impediment in Chinese medicine,has complex clinical symptoms.It is mostly caused by constitutional insufficiency,emotional disorder and improper diet combining external pathogen attack,resulting in dysfunction and interaction of five zang-organs,overconsumption and distribution dysfunction of yin,blood and fluid-humor,and failing to arrive at all limbs,bones and orifices.The paper elucidates the pathogenesis and diagnostic and therapeutic characteristics of dry impediment,and indicates the disease is related to all five zang-organs (heart,liver,spleen,lung,kidney) while most closely related to kidney,spleen and liver.The pathogenesis of the disease is based on deficiency of kidney yin and essence,and mainly dominated by dysfunction of spleen in transportation and block of liver's free activity.The treatment of the disease,based on pattern differentiation,commonly use therapies of nourishing yin and tonifying kidney,fortifying spleen and tonifying qi,soothing liver and activating blood,clearing lung-heat and moistening dryness,and nourishing heart and tranquilizing mind,meanwhile matched with nourishing blood and engendering fluid,freeing collateral vessels and relieving pain,and clearing heat and eliminating dampness.Among these therapies,nourishing yin,tonifying qi and activating blood are keys in treatment.
From the transition of classification criteria to view diagnosis and differential diagnosis of Sj(o)gren's syndrome

Li-qin XU,Jin LIN

DOI: https://doi.org/10.19538/j.nk2017060102

2017-01-01

Abstract:Sj(o)gren's syndrome is a chronic autoimmune disease,characterized by hypofunction of salivary and lacrimal glands and multisystem involvement.During the past decades,the most commonly used classification criteria is 2002 AECG criteria,and 2012 ACR criteria and 2016 ACR/EULAR new classification criteria had different characteristics.Sj(o)gren's syndrome has a wide spectrum of clinical manifestations.It needs to be differentiated from various diseases,including history of head and neck radiation treatment,active hepatitis C infection,AIDS,sarcoidosis,graft-versus-host disease,anti-acetylcholine drugs application,IgG4-related disease and lymphoma etc,in order to avoid misdiagnosis or missed diagnosis.
Sjogren’s syndrome: An update on disease pathogenesis, clinical manifestations and treatment

Frederick Vivino,Vatinee Y. Bunya,Giacomina Massaro-Giordano,Chadwick R. Johr,Stephanie L. Giattino,Annemarie Schorpion,Brian Shafer,Ammon Peck,Kathy Sivils,Astrid Rasmussen,John A. Chiorini,Jing He,Julian L. Ambrus

DOI: https://doi.org/10.1016/j.clim.2019.04.009

IF: 10.19

2019-01-01

Clinical Immunology

Abstract:•Sjogren's syndrome is reviewed from the clinical and research perspective.•It includes new ways about what causes the disease•It discusses how the disease can manifest•It discusses how the disease is currently treated and potential new therapies
Advances in Pathogenesis of Sjögren’s Syndrome

Yao Tian,Hongyi Yang,Na Liu,Yan Li,Jie Chen

DOI: https://doi.org/10.1155/2021/5928232

IF: 4.4929

2021-10-07

Journal of Immunology Research

Abstract:Sjögren’s syndrome (SS) is a chronic autoimmune disease of unknown etiology that mainly involves exocrine glands. Patients present with dry mouth and eyes, fever, arthralgia, and other systemic symptoms. In severe cases, the quality of life of patients is affected. At present, there is no cure for SS, and the treatment options are extremely limited. In recent years, studies of patients and animal models have identified abnormalities of immune cell function and cytokines to be involved in SS. A systematic review of the literature may clarify the etiology and pathogenesis of SS, as well as provide a theoretical basis for the development of new drugs for the treatment of SS.

immunology
Update on the pathophysiology and treatment of primary Sjögren syndrome

Chiara Baldini,Giovanni Fulvio,Gaetano La Rocca,Francesco Ferro

DOI: https://doi.org/10.1038/s41584-024-01135-3

Abstract:Sjögren syndrome or Sjögren disease is a chronic form of autoimmune epithelitis characterized by lymphocytic infiltration of the exocrine glands, particularly the salivary and lacrimal glands, leading to progressive glandular dysfunction and subsequent xerostomia and xerophthalmia. Other common manifestations include pain and fatigue, various systemic manifestations and non-Hodgkin's lymphoma. Sjögren syndrome is therefore a complex and disabling disease associated with a reduced quality of life and with considerable long-term damage. Most of the available treatments are merely symptomatic with limited efficacy in both preventing glandular damage and suppressing systemic disease activity. In the past 10 years, great progress has been made in understanding the pathophysiology of Sjögren syndrome, opening new avenues towards a more targeted and individualized therapeutic approach to the disease. Indeed, several randomized controlled trials have just been completed or are poised to commence evaluating the effectiveness of novel drugs targeting both innate and adaptive immune pathways, including pro-inflammatory cytokines, the type I interferon system, B cell activation, B cell and T cell co-stimulation pathway, and ectopic germinal centre formation. Novel clinical trials are also ongoing exploring various targeted approaches (that is, IgG recycling inhibition, nuclease therapy and CAR-T cell therapy) for Sjögren syndrome.
Early diagnosis and treatment for Sjögren's syndrome: current challenges, redefined disease stages and future prospects

Bin Wang,Shiju Chen,Qing Zheng,Yan Li,Xinwei Zhang,Jingxiu Xuan,Yuan Liu,Guixiu Shi

DOI: https://doi.org/10.1016/j.jaut.2020.102590

IF: 14.511

2021-02-01

Journal of Autoimmunity

Abstract:<p>There are some challenges and unmet needs in the early diagnosis and management of Sjögren's syndrome (SjS) such as prominent glandular dysfunction at diagnosis and long diagnostic delay. Those challenges are partly attributed to the lack of a good knowledge of the early stages of SjS, which is a major obstacle to delivering appropriate care to SjS patients. Findings from both clinical and experimental studies suggest the plausibility of a redefined SjS course consisting of 4 stages, which includes initiation stage, preclinical stage, asymptomatic SjS stage and overt SjS stage. More studies focusing on the pathological processes and changes during the early stages of SjS are needed. To enable early diagnosis and treatment for SjS, more useful biomarkers of the early stages of SjS need to be identified, and individuals at high risk of SjS development need to be identified. Appropriate screening can be performed to facilitate the early diagnosis of SjS among those high-risk individuals.</p>

immunology
Pathogenesis and treatment of Sjogren's syndrome: Review and update

Qipeng Zhan,Jianan Zhang,Yubin Lin,Wenjing Chen,Xinzou Fan,Dunfang Zhang

DOI: https://doi.org/10.3389/fimmu.2023.1127417

2023-02-02

Abstract:Sjogren's syndrome (SS) is a chronic autoimmune disease accompanied by multiple lesions. The main manifestations include dryness of the mouth and eyes, along with systemic complications (e.g., pulmonary disease, kidney injury, and lymphoma). In this review, we highlight that IFNs, Th17 cell-related cytokines (IL-17 and IL-23), and B cell-related cytokines (TNF and BAFF) are crucial for the pathogenesis of SS. We also summarize the advances in experimental treatment strategies, including targeting Treg/Th17, mesenchymal stem cell treatment, targeting BAFF, inhibiting JAK pathway, et al. Similar to that of SLE, RA, and MS, biotherapeutic strategies of SS consist of neutralizing antibodies and inflammation-related receptor blockers targeting proinflammatory signaling pathways. However, clinical research on SS therapy is comparatively rare. Moreover, the differences in the curative effects of immunotherapies among SS and other autoimmune diseases are not fully understood. We emphasize that targeted drugs, low-side-effect drugs, and combination therapies should be the focus of future research.
[Sjögren's disease: From pathophysiology to treatment]

Xavier Mariette

DOI: https://doi.org/10.1051/jbio/2024003

Abstract:Sjögren's disease (SjD) is a systemic autoimmune disorder characterized by a triad of key symptoms affecting almost all patients (salivary and lacrimal dryness, pain and fatigue) and extra-glandular systemic involvement affecting one to two-thirds of patients. Over the past decade, knowledge of the epidemiology, classification criteria, assessment of systemic activity and symptoms presented by patients has grown. In addition, advances in understanding the pathophysiology of SjD have enabled a more targeted therapeutic approach. Current management of SjD is based on EULAR treatment guidelines. But since these recommendations, new drugs targeting specific pathophysiological pathways of the disease, and essentially B lymphocyte activation, have shown efficacy in phase 2 trials. In this review, we will summarize the available evidence on systemic therapies, including: 1. advances in outcome assessment, 2. current evidence on targeted disease-modifying therapies and biologic drugs targeting primarily B lymphocytes, 3. an overview of promising drugs being tested in ongoing trials.
Management of Sjogren's Dry Eye Disease—Advances in Ocular Drug Delivery Offering a New Hope

Kevin Y. Wu,Wei T. Chen,Y-Kim Chu-Bédard,Gauri Patel,Simon D. Tran

DOI: https://doi.org/10.3390/pharmaceutics15010147

IF: 6.525

2023-01-01

Pharmaceutics

Abstract:Sjögren's syndrome is a chronic and insidious autoimmune disease characterized by lymphocyte infiltration of exocrine glands. Patients typically present with dry eye, dry mouth, and other systemic manifestations. Currently, the available molecules and drug-delivery systems for the treatment of Sjögren's syndrome dry eye (SSDE) have limited efficacy since they are not specific to SSDE but to dry eye disease (DED) in general. The current treatment modalities are based on a trial-and-error approach using primarily topical agents. However, this approach gives time for the vicious cycle of DED to develop which eventually causes permanent damage to the lacrimal functional unit. Thus, there is a need for more individualized, specific, and effective treatment modalities for SSDE. The purpose of this article is to describe the current conventional SSDE treatment modalities and to expose new advances in ocular drug delivery for treating SSDE. A literature review of the pre-clinical and clinical studies published between 2016 and 2022 was conducted. Our current understanding of SSDE pathophysiology combined with advances in ocular drug delivery and novel therapeutics will allow the translation of innovative molecular therapeutics from the bench to the bedside.

pharmacology & pharmacy
Special Issue, "Molecular Advances in Skin Diseases 2.0"

Naoko Kanda

DOI: https://doi.org/10.3390/ijms25115928

IF: 5.6

2024-05-30

International Journal of Molecular Sciences

Abstract:Recently, the pathomechanisms of various skin diseases have been progressively elucidated [...]

biochemistry & molecular biology,chemistry, multidisciplinary
Advances, limitations and future perspectives in the diagnosis and management of dry eye in Sjögren's syndrome

Jelle Vehof,Tor P Utheim,Hendrika Bootsma,Christopher J Hammond

Abstract:Primary Sjögren's syndrome is a complex systemic autoimmune disorder that primarily affects exocrine glands such as the lacrimal glands. Dry eye disease is one of the most prevalent complications of Sjögren's syndrome, affecting most patients. It significantly impairs quality of life and management is often difficult and unsatisfactory, in part due to weak correlation between symptoms and signs and poor recognition of the three main subtypes aqueous-deficient, evaporative and neuropathic dry eye. This review provides an overview of key aspects of dry eye disease, such as its multifactorial aetiology and recent insights into pathophysiology. The uses and pitfalls of commonly-used diagnostic tests for dry eye are reviewed, as well as the increasing number of new imaging technologies and biomarkers to refine diagnosis. There are many current and emerging treatment options for dry eye in Sjögren's syndrome, but high-level evidence of efficacy is mostly lacking, as are evidence-based treatment algorithms. All these aspects make the management of dry eye in Sjögren's syndrome challenging.
Outline of Salivary Gland Pathogenesis of Sjögren's Syndrome and Current Therapeutic Approaches

Yoshiaki Yura,Masakazu Hamada

DOI: https://doi.org/10.3390/ijms241311179

2023-07-06

Abstract:Sjögren's syndrome (SS) is an autoimmune disease characterized by the involvement of exocrine glands such as the salivary and lacrimal glands. The minor salivary glands, from which tissue samples may be obtained, are important for the diagnosis, evaluation of therapeutic efficacy, and genetic analyses of SS. In the onset of SS, autoantigens derived from the salivary glands are recognized by antigen-presenting dendritic cells, leading to the activation of T and B cells, cytokine production, autoantibody production by plasma cells, the formation of ectopic germinal centers, and the destruction of salivary gland epithelial cells. A recent therapeutic approach with immune checkpoint inhibitors for malignant tumors enhances the anti-tumor activity of cytotoxic effector T cells, but also induces SS-like autoimmune disease as an adverse event. In the treatment of xerostomia, muscarinic agonists and salivary gland duct cleansing procedure, as well as sialendoscopy, are expected to ameliorate symptoms. Clinical trials on biological therapy to attenuate the hyperresponsiveness of B cells in SS patients with systemic organ involvement have progressed. The efficacy of treatment with mesenchymal stem cells and chimeric antigen receptor T cells for SS has also been investigated. In this review, we will provide an overview of the pathogenesis of salivary gland lesions and recent trends in therapeutic approaches for SS.
The Future of Targeted Treatment of Primary Sjögren’s Syndrome: A Focus on Extra-Glandular Pathology

Weizhen Zeng,Xinyao Zhou,Sulan Yu,Ruihua Liu,Chrystie Wan Ning Quek,Haozhe Yu,Ryan Yong Kiat Tay,Xiang Lin,Yun Feng

DOI: https://doi.org/10.3390/ijms232214135

IF: 5.6

2022-01-01

International Journal of Molecular Sciences

Abstract:Primary Sjögren’s syndrome (pSS) is a chronic, systemic autoimmune disease defined by exocrine gland hypofunction resulting in dry eyes and dry mouth. Despite increasing interest in biological therapies for pSS, achieving FDA-approval has been challenging due to numerous complications in the trials. The current literature lacks insight into a molecular-target-based approach to the development of biological therapies. This review focuses on novel research in newly defined drug targets and the latest clinical trials for pSS treatment. A literature search was conducted on ClinicalTrials.gov using the search term “Primary Sjögren’s syndrome”. Articles published in English between 2000 and 2021 were included. Our findings revealed potential targets for pSS treatment in clinical trials and the most recent advances in understanding the molecular mechanisms underlying the pathogenesis of pSS. A prominent gap in current trials is in overlooking the treatment of extraglandular symptoms such as fatigue, depression, and anxiety, which are present in most patients with pSS. Based on dryness and these symptom-directed therapies, emerging biological agents targeting inflammatory cytokines, signal pathways, and immune reaction have been studied and their efficacy and safety have been proven. Novel therapies may complement existing non-pharmacological methods of alleviating symptoms of pSS. Better grading systems that add extraglandular symptoms to gauge disease activity and severity should be created. The future of pSS therapies may lie in gene, stem-cell, and tissue-engineering therapies.
Challenges in Treatment of Primary Sjögren’s Syndrome and Opportunities for Chinese Medicine

Jia-qi Hou,Luan Xue

DOI: https://doi.org/10.1007/s11655-019-3226-0

IF: 2.9

2019-12-23

Chinese Journal of Integrative Medicine

Abstract:Primary Sjögren's syndrome is a chronic autoimmune disease that can lead to systemic manifestations. At present, immunomodulatory agents have not shown good efficacy, many patients in China seek Chinese medicine treatment. Chinese medicine can comprehensively improve the symptoms of patients through Chinese pattern diagnosis and individualized treatment. Fundamental researches are providing scientific bases for the therapeutic effect of Chinese medicine. Professional Chinese medicine treatment can be integrated into the conventional management of primary Sjögren's syndrome.

integrative & complementary medicine
Application of omics in Sjögren's syndrome

Wenqin He,Yangyang Lu,Rongjing Shi,Qi An,Jingwen Zhao,Xinnan Gao,Liyun Zhang,Dan Ma

DOI: https://doi.org/10.1007/s00011-023-01797-x

IF: 6.986

2023-10-27

Inflammation Research

Abstract:The pathogenesis, diagnosis, and treatment of Sjögren's syndrome (SS) face many challenges, and there is an urgent need to develop new technologies to improve our understanding of SS.

immunology,cell biology
Das Sjögren-Syndrom im Fokus

Nadine Zehrfeld,Torsten Witte,Diana Ernst

DOI: https://doi.org/10.1055/a-2136-3498

2024-05-24

DMW - Deutsche Medizinische Wochenschrift

Abstract:Diagnostik – Der Teufel steckt im Detail! Die Speicheldrüsensonografie (SGUS) hat sich in der Diagnostik des Sjögren-Syndroms (SjS) etabliert und kann zu einer höheren Sensitivität der geltenden Klassifikationskriterien führen, gleichwohl sie bislang nicht in die Kriterien aufgenommen wurde. In der Labordiagnostik erhalten die Subspezifizierung von anti-SSA/Ro-Antikörpern – ggf. auch neue Biomarker – eine zunehmende Bedeutung. Präventiv müssen psychische Belastungen im Auge behalten werden, und das kardiovaskuläre Risiko und das Lymphomrisiko spielen eine große Rolle. Mittels Cluster-Analysen konnten verschiedene Phänotyp-Gruppen erschlossen werden, denen sich klinische Parameter zuordnen lassen. Therapie 2020 wurden Therapieempfehlungen publiziert, die sich an den klinischen Manifestationen des SjS orientieren und Medikamente empfehlen, die auch in der Therapie des systemischen Lupus erythematodes (SLE) oder bei der rheumatoiden Arthritis eingesetzt werden. In den EULAR-Empfehlungen hat die Anti-B-Zell-Therapie mit Rituximab und Belimumab für schwerwiegende Manifestationen Einzug gefunden, und Ianalumab ist ein weiterer aussichtsreicher Wirkstoff. Ein weiterer Schwerpunkt der aktuellen Forschung liegt in der Inhibition der Costimulation zwischen Immunzellen. Nach zuletzt enttäuschenden Ergebnissen von Abatacept sind mit Iscalimab und Dazodalibep aber auch auf dieser Therapieachse aussichtsreiche Wirkstoffe in der Pipeline. In the diagnosis of Sjögren's syndrome the Salivary gland sonography (SGUS) has become established and can lead to a higher specificity of the applicable classification criteria. The OMERACT score is used to objectify the SGUS findings. In laboratory diagnostics, the subspecification of anti-SSA/Ro antibodies, but possibly also new biomarkers, are becoming increasingly important regarding diagnostic safety and the expected manifestations. When it comes to prevention, it has been shown that not only psychological stress, but also cardiovascular risk and the risk of lymphoma allow high-risk patients to be identified more precisely in the future. Using cluster analyses, various phenotype groups could be identified to which clinical parameters could be assigned. In 2020, therapy recommendations were published that are based on the clinical manifestations of SjS and recommend medications that are also used in the treatment of systemic lupus erythematosus (SLE) or rheumatoid arthritis. A particularly large number of therapeutic approaches are dedicated to the B cell: Rituximab and Belimumab have been included in the EULAR recommendations for serious manifestations and Ianalumab has a promising effect. Another focus of current research is the inhibition of co-stimulation between immune cells. After recent disappointing results for Abatacept, clinical trials show promising effects on Iscalimab and Dazodalibep. Article published online: 23 May 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

medicine, general & internal
Advances in Sjögren's Syndrome Dry Eye Diagnostics: Biomarkers and Biomolecules beyond Clinical Symptoms

Kevin Y. Wu,Olivia Serhan,Anne Faucher,Simon D. Tran

DOI: https://doi.org/10.3390/biom14010080

IF: 6.064

2024-01-09

Biomolecules

Abstract:Sjögren's syndrome dry eye (SSDE) is a subset of Sjögren's syndrome marked by dry eye symptoms that is distinct from non-Sjögren's syndrome dry eye (NSSDE). As SSDE can lead to severe complications, its early detection is imperative. However, the differentiation between SSDE and NSSDE remains challenging due to overlapping clinical manifestations. This review endeavors to give a concise overview of the classification, pathophysiology, clinical features and presentation, ocular and systemic complications, clinical diagnosis, and management of SSDE. Despite advancements, limitations in current diagnostic methods underscore the need for novel diagnostic modalities. Thus, the current review examines various diagnostic biomarkers utilized for SSDE identification, encompassing serum, salivary, and tear analyses. Recent advancements in proteomic research and exosomal biomarkers offer promising diagnostic potential. Through a comprehensive literature review spanning from 2016 to 2023, we highlight molecular insights and advanced diagnostic modalities that have the potential to enhance our understanding and diagnosis of SSDE.

biochemistry & molecular biology
Immunobiology of T Cells in Sjögren’s Syndrome

Yao Yuan,Ma Jin-Fen,Joe DiMaggio Children’s Hospital,Xu Ting,Gao Cai-Yue,Gershwin M. Eric,Lian Zhe-Xiong

DOI: https://doi.org/10.1007/s12016-020-08793-7

2020-01-01

Clinical Reviews in Allergy & Immunology

Abstract:Sjögren’s syndrome (SjS) is a systemic autoimmune disease marked by xerostomia (dry mouth), keratoconjunctivitis sicca (eye dryness), and other systematic disorders. Its pathogenesis involves an inflammatory process that is characterized by lymphocytic infiltration into exocrine glands and other tissues. Although the development of ectopic lymphoid tissue and overproduction of autoantibodies by hyperactive B cells suggest that they may promote SjS development, treatment directed towards them fails to induce significant laboratory or clinical improvement. T cells are overwhelming infiltrators in most phases of the disease, and the involvement of multiple T cell subsets of suggests the extraordinary complexity of SjS pathogenesis. The factors, including various cellular subtypes and molecules, regulate the activation and suppression of T cells. T cell activation induces inflammatory cell infiltration, B cell activation, tissue damage, and metabolic changes in SjS. Knowledge of the pathways that link these T cell subtypes and regulation of their activities are not completely understood. This review comprehensively summarizes the research progress and our understanding of T cells in SjS, including CD4+ T cells, CD8+ TRM cells, and innate T cells, to provide insights into for clinical treatment.
Recent Advances in Pathology: the 2020 Annual Review Issue of The Journal of Pathology

C Simon Herrington,Richard Poulsom,Philip J Coates

DOI: https://doi.org/10.1002/path.5425

Abstract:This year's Annual Review Issue of The Journal of Pathology contains 18 invited reviews on current research areas in pathology. The subject areas reflect the broad range of topics covered by the journal and this year encompass the development and application of software in digital histopathology, implementation of biomarkers in pathology practice; genetics and epigenetics, and stromal influences in disease. The reviews are authored by experts in their field and provide comprehensive updates in the chosen areas, in which there has been considerable recent progress in our understanding of disease. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Recent Advances in Pathogenesis, Diagnostic Imaging, and Treatment of Sjögren's Syndrome

Advances in the Pathogenesis and Treatment of Primary Sj(o)gren's Syndrome

Pathogenesis and diagnostic and therapeutic characteristics of Sjogren's syndrome based on TCM theory of five zang-organs

From the transition of classification criteria to view diagnosis and differential diagnosis of Sj(o)gren's syndrome

Sjogren’s syndrome: An update on disease pathogenesis, clinical manifestations and treatment

Advances in Pathogenesis of Sjögren’s Syndrome

Update on the pathophysiology and treatment of primary Sjögren syndrome

Early diagnosis and treatment for Sjögren's syndrome: current challenges, redefined disease stages and future prospects

Pathogenesis and treatment of Sjogren's syndrome: Review and update

[Sjögren's disease: From pathophysiology to treatment]

Management of Sjogren's Dry Eye Disease—Advances in Ocular Drug Delivery Offering a New Hope

Special Issue, "Molecular Advances in Skin Diseases 2.0"

Advances, limitations and future perspectives in the diagnosis and management of dry eye in Sjögren's syndrome

Outline of Salivary Gland Pathogenesis of Sjögren's Syndrome and Current Therapeutic Approaches

The Future of Targeted Treatment of Primary Sjögren’s Syndrome: A Focus on Extra-Glandular Pathology

Challenges in Treatment of Primary Sjögren’s Syndrome and Opportunities for Chinese Medicine

Application of omics in Sjögren's syndrome

Das Sjögren-Syndrom im Fokus

Advances in Sjögren's Syndrome Dry Eye Diagnostics: Biomarkers and Biomolecules beyond Clinical Symptoms

Immunobiology of T Cells in Sjögren’s Syndrome

Recent Advances in Pathology: the 2020 Annual Review Issue of The Journal of Pathology